BriaCell Therapeutics Corp. Holds Annual General Meeting of ShareholdersOn February 5, 2025, BriaCell Therapeutics Corp. (NASDAQ:BCTX) conducted its Annual General Meeting of Shareholders, where crucial company matters were discussed and voted upon.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read BriaCell Therapeutics’s 8K filing here.

About BriaCell Therapeutics

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.